Last reviewed 2026-04-23 · How we verify

NCX 470 0.1%

Nicox Ophthalmics, Inc. · Phase 3 active Small molecule

NCX 470 0.1% is a Nitric oxide-donating prostaglandin F analog Small molecule drug developed by Nicox Ophthalmics, Inc.. It is currently in Phase 3 development for Open-angle glaucoma, Ocular hypertension. Also known as: NCX 470.

NCX 470 is a nitric oxide-donating prostaglandin F analog that lowers intraocular pressure by increasing uveoscleral outflow and releasing nitric oxide to enhance trabecular outflow.

NCX 470 is a nitric oxide-donating prostaglandin F analog that lowers intraocular pressure by increasing uveoscleral outflow and releasing nitric oxide to enhance trabecular outflow. Used for Open-angle glaucoma, Ocular hypertension.

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	NCX 470 0.1%
Also known as	NCX 470
Sponsor	Nicox Ophthalmics, Inc.
Drug class	Nitric oxide-donating prostaglandin F analog
Target	Prostaglandin F receptor (FP receptor); nitric oxide pathway
Modality	Small molecule
Therapeutic area	Ophthalmology
Phase	Phase 3

Mechanism of action

NCX 470 combines the intraocular pressure-lowering effects of a prostaglandin F analog with nitric oxide donation. Nitric oxide enhances aqueous humor drainage through both the conventional (trabecular) and unconventional (uveoscleral) pathways. This dual mechanism may provide superior efficacy compared to prostaglandin analogs alone in reducing intraocular pressure in glaucoma patients.

Approved indications

Open-angle glaucoma
Ocular hypertension

Common side effects

Conjunctival hyperemia
Eye irritation
Increased iris pigmentation
Eyelash growth

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NCX 470 0.1% CI brief — competitive landscape report
NCX 470 0.1% updates RSS · CI watch RSS
Nicox Ophthalmics, Inc. portfolio CI

Frequently asked questions about NCX 470 0.1%

What is NCX 470 0.1%?

NCX 470 0.1% is a Nitric oxide-donating prostaglandin F analog drug developed by Nicox Ophthalmics, Inc., indicated for Open-angle glaucoma, Ocular hypertension.

How does NCX 470 0.1% work?

NCX 470 is a nitric oxide-donating prostaglandin F analog that lowers intraocular pressure by increasing uveoscleral outflow and releasing nitric oxide to enhance trabecular outflow.

What is NCX 470 0.1% used for?

NCX 470 0.1% is indicated for Open-angle glaucoma, Ocular hypertension.

Who makes NCX 470 0.1%?

NCX 470 0.1% is developed by Nicox Ophthalmics, Inc. (see full Nicox Ophthalmics, Inc. pipeline at /company/nicox-ophthalmics-inc).

Is NCX 470 0.1% also known as anything else?

NCX 470 0.1% is also known as NCX 470.

What drug class is NCX 470 0.1% in?

NCX 470 0.1% belongs to the Nitric oxide-donating prostaglandin F analog class. See all Nitric oxide-donating prostaglandin F analog drugs at /class/nitric-oxide-donating-prostaglandin-f-analog.

What development phase is NCX 470 0.1% in?

NCX 470 0.1% is in Phase 3.

What are the side effects of NCX 470 0.1%?

Common side effects of NCX 470 0.1% include Conjunctival hyperemia, Eye irritation, Increased iris pigmentation, Eyelash growth.

What does NCX 470 0.1% target?

NCX 470 0.1% targets Prostaglandin F receptor (FP receptor); nitric oxide pathway and is a Nitric oxide-donating prostaglandin F analog.

Drug class: All Nitric oxide-donating prostaglandin F analog drugs
Target: All drugs targeting Prostaglandin F receptor (FP receptor); nitric oxide pathway
Manufacturer: Nicox Ophthalmics, Inc. — full pipeline
Therapeutic area: All drugs in Ophthalmology
Indication: Drugs for Open-angle glaucoma
Indication: Drugs for Ocular hypertension
Also known as: NCX 470

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing